Generic Medicine Info
Indications and Dosage
Adult: Initially, 5 mg once daily. 1st dose preferably given at bedtime to avoid precipitous fall in BP. Maintenance: 10 mg/day. Max: 20 mg/day. Patients on diuretics: 2.5 mg daily.
Elderly: Initially, 2.5 mg daily. Max Dose: 10 mg daily.
Renal Impairment
Initially, 2.5 mg/day.
Hepatic Impairment
Initially, 2.5 mg/day.
Should be taken on an empty stomach. Take 15 min before meals. However, when initiating therapy, 1st dose should be given at bedtime.
History of angioneurotic oedema related w/ previous ACE inhibitor therapy. Hereditary or idiopathic angioedema. Pregnancy.
Special Precautions
Renal artery stenosis; collagen vascular disease, heart failure; at risk for hypotension (e.g. volume-depleted patients). Renal and hepatic impairment. Lactation.
Adverse Reactions
Dizziness, headache, fatigue, somnolence, GI and taste disturbances, persistent dry cough and other upper resp tract symptoms, hyperkalaemia, hyponatraemia, blood disorders (e.g. neutropenia, agranulocytosis, anaemia, thrombocytopenia).
Potentially Fatal: Severe hypotension, which could result in MI or stroke in patients w/ ischaemic heart disease or cerebrovascular disease. Rarely, fulminant hepatic necrosis.
Monitoring Parameters
Assess renal function before and during the 1st wk of therapy. Monitor serum electrolytes and creatinine levels frequently.
Symptoms: Severe hypotension, bradycardia, shock, stupor, electrolyte disturbances and renal failure. Management: Perform haemodialysis and gastric lavage. Administer adsorbents and Na sulfate w/in 30 min of ingestion.
Drug Interactions
Marked hypotension w/ diuretics, other antihypertensives, and vasodilators, TCAs, neuroleptics. Additive hyperkalaemic effects w/ K-sparing diuretics, K supplements, and K-containing salt substitutes. Reduced antihypertensive effects or additive nephrotoxic effects w/ NSAIDs, rifampicin, sympathomimetics. Increased lithium levels and toxicity. May cause nitritoid reactions w/ injectable gold (Na aurothiomalate).
Description: Imidapril, a prodrug of imidaprilat, inhibits ACE from converting angiotensin I to angiotension II (a potent vasoconstrictor) resulting in increased plasma renin activity and reduced aldosterone (a hormone that causes water and Na retention) secretion. This promotes vasodilation and BP reduction. It may also inhibit the degradation of bradykinin.
Absorption: Rapidly but incompletely absorbed (approx 70%) from the GI tract. Reduced absorption w/ food. Absolute bioavailability: Approx 42% (imidaprilat). Time to peak plasma concentration: Approx 7 hr (imidaprilat).
Distribution: Plasma protein binding: 85% (imidapril); 53% (imidaprilat).
Metabolism: Hepatically hydrolysed to imidaprilat (active metabolite).
Excretion: Via urine (approx 40%); faeces (approx 50%). Terminal half-life: >24 hr.
Store below 30°C.
MIMS Class
ACE Inhibitors/Direct Renin Inhibitors
Anon. Imidapril: International Drug Information. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 21/11/2013.

Buckingham R (ed). Imidapril. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 21/11/2013.

Disclaimer: This information is independently developed by MIMS based on Imidapril from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 MIMS. All rights reserved. Powered by
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign up for free
Already a member? Sign in